Use of saxagliptin [Onglyza] is now contraindicated in patients with a history of serious hypersensitivity reaction to a
- PDF / 136,374 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 80 Downloads / 153 Views
1
■ Use of saxagliptin [Onglyza] is now contraindicated in patients with a history of serious hypersensitivity reaction to any DPP-4 inhibitor, announce Bristol-Myers Squibb (BMS) and AstraZeneca in a ‘Dear Healthcare Professional’ letter issued in the UK. Several serious reports of angioedema and associated events, and reports of anaphylactic reactions, have been identified in patients using the antihyperglycaemic. These have included reports of positive rechallenge. The product labelling for Onglyza has also been updated with information regarding the associated risk of acute pancreatitis. Pancreatitis is a recognised adverse events associated with other DPP-4 inhibitors, and there have been some postmarketing reports, in which pancreatitis has occurred after initiation of saxagliptin and resolved after discontinuation, which is suggestive of a causal relationship. Lones R. Direct Healthcare Professional Communication on the association of saxagliptin (Onglyza) with serious hypersensitivity reactions and acute pancreatitis. Internet Document : 8 Mar 2012. Available from: URL: http:// 803068961 www.mhra.gov.uk
0114-9954/10/1396-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 7 Apr 2012 No. 1396
Data Loading...
